贝特类药物与原发性胆汁性胆管炎无移植生存的关联
日本全国性回顾性队列纳入2000年起接受UDCA治疗且随访≥1年的3908例PBC患者,比较联合BZF与单用UDCA的生存差异。联合治疗与全因及肝病相关死亡或需肝移植风险显著降低相关,调整后风险比分别为0.3253和0.2748(P<0.001)。
要点
- UDCA联合BZF与PBC患者全因及肝病相关死亡或肝移植风险显著降低相关。
- 该关联在基线不同风险组中一致,5年、10年、15年预防1例死亡或肝移植的NNT分别为29、14、8。
- BZF是目前PBC中唯一在症状、生化指标和长期结局均显示疗效的药物。
核心结论
- 在大型回顾性队列中,UDCA基础上加用BZF与PBC患者预后改善相关。
研究设计与样本
- 日本全国性回顾性队列,纳入2000年起开始UDCA治疗且随访≥1年的连续登记PBC患者3908例。
- 采用时间依赖、多变量及倾向评分调整的Cox比例风险模型评估BZF暴露与死亡或肝移植的关联。
主要发现
- 3908例中3162例(81%)单用UDCA,746例(19%)联合BZF,随访患者年分别为17360和3932。
- 随访期间记录183例死亡(89例肝病相关)和21例肝移植。
- 联合治疗与全因死亡或需肝移植风险降低相关,调整后HR 0.3253(95%CI 0.1936-0.5466,P<0.001)。
- 联合治疗与肝病相关死亡或需肝移植风险降低相关,调整后HR 0.2748(95%CI 0.1336-0.5655,P<0.001)。
- 该关联在基线各风险组中一致;5、10、15年预防1例额外死亡或肝移植的NNT分别为29(95%CI 22-46)、14(10-22)、8(6-15)。
临床怎么用
- 对UDCA应答不完全的PBC患者,可考虑加用BZF以改善长期无移植生存。
- BZF联合UDCA的获益在基线不同风险组中一致,支持其作为二线治疗选择。
局限性
- 本研究为回顾性队列研究,非随机对照试验。
- 长期生存获益仍需进一步前瞻性研究确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: A beneficial effect of bezafibrate (BZF) on symptoms and biochemical features of primary biliary cholangitis (PBC) has been reported in patients with an incomplete response to ursodeoxycholic acid (UDCA), but long-term effects on survival remain unknown. In Japan, BZF has been used as a de facto second-line therapy for PBC since 2000. Herein, we compared the survival rates between patients treated with and those without BZF in a large nationwide Japanese PBC cohort. METHODS: All consecutively registered patients of this cohort who started UDCA therapy from 2000 onwards and had a follow-up ≥1 year were included. Association between BZF exposure and mortality or need for liver transplantation (LT) was assessed using time-dependent, multivariable-and propensity score-adjusted Cox proportional hazards models. Clinical benefit was quantified using the number needed to treat (NNT). RESULTS: Of 3,908 eligible patients, 3,162 (81%) received UDCA only and 746 (19%) UDCA and BZF over 17,360 and 3,932 patient-years, respectively. During follow-up, 183 deaths (89 liver-related) and 21 LT were registered. Exposure to combination therapy was associated with a significant decrease in all-cause and liver-related mortality or need for LT (adjusted hazard ratios: 0.3253, 95% CI 0.1936-0.5466 and 0.2748, 95% CI 0.1336-0.5655, respectively; p <0.001 for both). This association was consistent across various risk groups at baseline. The NNTs with combination therapy to prevent 1 additional death or LT over 5, 10, and 15 years were 29 (95% CI 22-46), 14 (10-22), and 8 (6-15), respectively. CONCLUSIONS: In a large retrospective cohort study of treatment effects in patients with PBC, the addition of BZF to UDCA was associated with improved prognosis. LAY SUMMARY: The long-term efficacy of bezafibrate (BZF) on liver transplantation (LT) - free survival in patients with PBC and an incomplete response to ursodeoxycholic acid (UDCA) remains to be determined. In this Japanese nationwide retrospective cohort study, the use of UDCA-BZF combination therapy, compared to UDCA alone, was associated with a lower risk of all-cause and liver-related mortality or need for LT. These results indicate that BZF is so far the only drug in PBC to have demonstrated efficacy in improving symptoms, biochemical markers, and long-term outcomes.
引用
- Tanaka A, Hirohara J, Nakano T, et al. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021. PMID: 33882268. doi:10.1016/j.jhep.2021.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。